Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells

(2011) Rebekka Wehner et al.   Journal of Innate Immunity

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells

(2010) Maria-Elena Márquez et al.   CELLULAR IMMUNOLOGY

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck

(2010) Mark E. Sharafinski et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

The Interactions of Multiple Cytokines Control NK Cell Maturation

(2010) J. Brady et al.   JOURNAL OF IMMUNOLOGY

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma

(2009) M Watanabe et al.   BRITISH JOURNAL OF CANCER

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dendritic Cells and their Receptors in Antitumor Immune Response

(2009) Raghvendra Srivastava et al.   CURRENT MOLECULAR MEDICINE

Ten years of rituximab in NHL

(2009) Matthew C Winter et al.   Expert Opinion On Drug Safety

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function

(2009) Andrés López-Albaitero et al.   JOURNAL OF IMMUNOTHERAPY

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Cetuximab, chemotherapy and KRAS status in mCRC

(2009) Sharlene Gill et al.   Nature Reviews Clinical Oncology

Cetuximab for Metastatic Colorectal Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

(2008) Masayasu Hara et al.   CANCER SCIENCE

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating Fc??Rs on Human Dendritic Cells

(2008) Devi Banerjee et al.   JOURNAL OF IMMUNOTHERAPY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE